GENEVA--(BUSINESS WIRE)--Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology, announced today its planned participation at several industry conferences during the first quarter of 2019. Details follow.
Industry Strategy Symposium - ISS 2019
6 – 9 January
2019, The Ritz-Carlton, Half Moon Bay, California
Selexis
Chief Executive Officer, Igor Fisch, PhD will present at the
conference on “The ‘Biotechnology Revolution’ - Semiconductor and
Superconductor Technologies Give Birth to New Fields in Life Sciences”
on Monday, January 7 at 2:05 p.m. PT as part of the “Market Perspective”
track. For more information, please visit: http://www1.semi.org/en/industry-strategy-symposium-iss-2019
FULL ABSTRACT: Biotechnology is considered the revolution of the 21st Century. Semi- and superconductor technologies have led to dramatic advances in computers, biosensors, artificial intelligence (AI) and the development of new biomaterials that have given birth to the fields of proteomics, bioinformatics, nanotechnology, gene therapy, pharmacogenetics, etc. We will look at the role semiconductors play in today’s biotechnology landscape and tomorrow’s medicines.
J.P. Morgan 37th Annual Healthcare Conference
7
– 10 January 2019, San Francisco, California
Representatives
from Selexis business development will attend the conference, along with
KBI Biopharma, and will participate in partnering discussions. To
schedule a meeting, visit: http://selexis.com/contact/
PEPTALK 2019
14 – 18 January 2019, Hilton San Diego
Bayfront, San Diego, California
Selexis will present, sponsor
and exhibit at the conference.
Selexis
Chief Scientific Officer, Pierre-Alain Girod, PhD will
present “Research Cell Bank Generation in under 14 Weeks: Integrating
Single Cell Analysis into the SUREtechnology Platform” on
Tuesday, January 15 at 12:00 p.m. PT as part of the CHO Cell Line
Development and Engineering track. Visit Selexis at Booth 512. For more
information, see: http://www.chi-peptalk.com/
FULL ABSTRACT: Currently, Selexis’ SUREtechnology Platform™ generates research cell banks in as little as 14 weeks, with optimal clone selection requiring 6-8 of those weeks. Single cell analysis platforms, capable of parallel analyses, have the capacity to reduce those timelines, but must be optimized to each cell system. Selexis has integrated the BEACON® optofluidic platform into the SUREtechnology workflow plus developed a clone prediction tool that collectively shave weeks off the current development timelines. Case studies will be discussed.
BIO Asia International Conference
5 – 6 March 2019, Grand
Hyatt Roppongi, Tokyo, Japan
Representatives from Selexis
business development will attend the conference and will participate in
partnering discussions. For more information, please visit: https://www.bio.org/events/bio-asia-international-conference
BioPH/CPhI
18 – 20 March 2019, Big Sight
Exhibition Center, Tokyo, Japan
Representatives from Selexis
business development will attend the conference and will participate in
partnering discussions. For more information, please visit: https://www.cphi.com/japan/
BIO-Europe Spring
25 – 27 March 2019, Messe Wien
Exhibition and Congress Center, Vienna, Austria
Representatives
from Selexis business development will attend the conference and will
participate in the partnering program. Schedule a partnering meeting at https://ebdgroup.knect365.com/bioeurope-spring/
About Selexis SA
Selexis SA is the global leader in cell
line development with best-in-class modular technology and highly
specialized solutions that enable the life sciences industry to rapidly
discover, develop and commercialize innovative medicines and vaccines.
Our global partners are utilizing Selexis technologies to advance more
than 100 drug products in clinical development and the manufacture of
four commercial products. As part of a comprehensive drug development
process, the Company’s technologies shorten development timelines and
reduce manufacturing risks. In June 2017, Selexis became part of the JSR
Life Sciences group. JSR’s CDMO service offering leverages the full
capabilities of Selexis’ proprietary SUREtechnology Platform™ to
offer an end-to-end solution to industry. More information is available
at www.selexis.com.
|
FOR MORE INFORMATION |
|||||
| - Web | |||||
